Listen: VC turmoil, GLP-1 competition, & the war on recovery
This week on "The Readout LOUD": Why are addiction treatments so hard to get? Can small companies compete in obesity? And since when is "Series E" a thing in biotech?
Why are addiction treatments so hard to get? Can small companies compete in obesity? And since when is “Series E” a thing in biotech?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives. STAT’s Lev Facher joins us to explain his reporting on why virtually every sector of American society is standing in the way of their use. We also discuss the latest news in the life sciences, including the haves and have-nots of venture capital, and the race to develop effective oral treatments for obesity.
What's Your Reaction?
